Arno Therapeutics, Inc.
ARNI · OTC
9/30/2016 | 6/30/2016 | 3/31/2016 | 12/31/2015 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $2 | $2 | $2 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $3 |
| Operating Income | -$2 | -$3 | -$3 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | $1 | -$1 | -$1 |
| Pre-Tax Income | -$4 | -$2 | -$4 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$2 | -$4 | -$4 |
| % Margin | – | – | – | – |
| EPS | -0.086 | -0.052 | -0.096 | -0.2 |
| % Growth | -66.9% | 46.3% | 52% | – |
| EPS Diluted | -0.086 | -0.052 | -0.096 | -0.2 |
| Weighted Avg Shares Out | 45 | 42 | 39 | 20 |
| Weighted Avg Shares Out Dil | 45 | 42 | 39 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$2 | -$3 | -$3 |
| % Margin | – | – | – | – |